Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
10.1245/s10434-007-9487-4
Annals of Surgical Oncology 14:2702-2713 (2007)
© 2007 Society of Surgical Oncology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yan, T. D.
Right arrow Articles by Morris, D. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Yan, T. D.
Right arrow Articles by Morris, D. L.

Original Article

A Systematic Review and Meta-analysis of the Randomized Controlled Trials on Adjuvant Intraperitoneal Chemotherapy for Resectable Gastric Cancer

Tristan D. Yan, BSc (Med) MBBS1,2, Deborah Black, BSc DipEd Mstat PhD3, Paul H. Sugarbaker, MD2, Jacqui Zhu, BSc (Med)4, Yutaka Yonemura, MD, PhD5, George Petrou, BSc (Med) MBBS1 and David L. Morris, MD, PhD1

1 Department of Surgery, University of New South Wales, St George Hospital, Sydney, NSW, Australia
2 Department of Surgical Oncology, Washington Cancer Institute, Washington Hospital Center, Washington, DC, USA
3 School of Public Health and Community Medicine, University of New South Wales, Sydney, NSW, Australia
4 School of Medicine, University of New South Wales, Sydney, NSW, Australia
5 Department of Gastric Cancer, Shizuoka Cancer Center, Shizuoka, Japan

Correspondence: Address correspondence and reprint requests to: Tristan D. Yan, BSc (Med) MBBS; E-mail: Tristan.Yan{at}unsw.edu.au

Background: The purpose of this systematic review and meta-analysis was to determine the effectiveness and safety of adjuvant intraperitoneal chemotherapy for patients with locally advanced resectable gastric cancer.

Methods: Studies eligible for this systematic review included those in which patients with gastric cancer were randomly assigned to receive surgery combined with intraperitoneal chemotherapy versus surgery without intraperitoneal chemotherapy. There were no language restrictions. After independent quality assessment and data extraction, data were pooled for meta-analysis.

Results: Thirteen reports of randomized controlled trials (RCTs) were included for quality appraisal and data extraction. Ten reports were judged to be of fair quality and subjected to meta-analysis. A significant improvement in survival was associated with hyperthermic intraoperative intraperitoneal chemotherapy (HIIC) alone (hazard ratio [HR] = 0.60; 95% CI = 0.43 to 0.83; p = 0.002) or HIIC combined with early postoperative intraperitoneal chemotherapy (EPIC) (HR = 0.45; 95% CI = 0.29 to 0.68; p = 0.0002). There was a trend towards survival improvement with normothermic intraoperative intraperitoneal chemotherapy (p = 0.06), but this was not significant with either EPIC alone or delayed postoperative intraperitoneal chemotherapy. Intraperitoneal chemotherapy was also found to be associated with higher risks of intra-abdominal abscess (RR = 2.37; 95% CI = 1.32 to 4.26; p = 0.003) and neutropenia (RR = 4.33; 95% CI = 1.49 to 12.61; p = 0.007).

Conclusions: The present meta-analysis indicates that HIIC with or without EPIC after resection of advanced gastric primary cancer is associated with improved overall survival. However, increased risk of intra-abdominal abscess and neutropenia are also demonstrated.

Key Words: Gastric carcinoma • Intraperitoneal chemotherapy






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the Society of Surgical Oncology.